Phase 3 Readout~month

Phase 3 Topline: A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in S

Name: Phase 3 Topline: A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in S
Start: 2030-01-01

January 1, 2030

Company: Cogent Biosciences, Inc. (COGT)
Drug: cgt9486
Indication: Metastatic Cancer; Advanced Gastrointestinal Stromal Tumors

Track this catalyst and more

Get real-time alerts, AI-powered analysis, and full catalyst coverage.

Start Free Full Calendar

Phase 3 Topline: A Phase 3 Randomized, Open-Label, Multicenter Clinical Study of CGT9486+Sunitinib vs. Sunitinib in S — COGT Phase 3 Readout | BioSniper